{"entity":{"id":"nct02717611","kind":"trial","name":"A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy","aka":[],"tldr":"A phase 2 trial of Acalabrutinib in chronic lymphocytic leukaemia, run by Acerta Pharma BV, active and no longer recruiting.","summary":"A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy is a phase 2 interventional study registered as NCT02717611 by Acerta Pharma BV, with 60 participants enrolled, started 2016-03-08 and due to reach its primary completion in 2020-10-16. Interventions recorded: ACP-196 (acalabrutinib). Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02717611","url":"https://clinicaltrials.gov/study/NCT02717611"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cll","cll-relapsed"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["acalabrutinib"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02717611","phase":"2","setting":"A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy","sponsor":"Acerta Pharma BV","started":"2016-03-08","startedType":"actual","yearReported":2022,"enrolled":60,"enrolledBasis":"registry","outcomes":[{"endpoint":"The Overall Response Rate (ORR) of ACP-196 (Acalabrutinib)","primary":true,"unit":"%","arms":[{"name":"Acalabrutinib","n":60,"value":70,"note":"95% CI 56.8 to 81.2; Figures from the ClinicalTrials.gov results section (first posted 2022-02-09), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT02717611?tab=results"}]},"route":"/trials/nct02717611/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"cll-relapsed","kind":"cancer","name":"Relapsed or refractory chronic lymphocytic leukaemia","route":"/cancers/cll-relapsed/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}